CAR T cells produced in vivo to treat cardiac injury

Science, Год журнала: 2022, Номер 375(6576), С. 91 - 96

Опубликована: Янв. 6, 2022

Fibrosis affects millions of people with cardiac disease. We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modified messenger RNA (mRNA) cell–targeted lipid nanoparticles (LNPs). The efficacy these vivo–reprogrammed CAR was evaluated injecting CD5-targeted LNPs into mouse model heart failure. Efficient delivery mRNA encoding the lymphocytes observed, which produced transient, effective vivo. Antifibrotic exhibited trogocytosis and retained target as they accumulated spleen. Treatment mRNA-targeted reduced fibrosis restored function after injury. In generation may hold promise platform treat various diseases.

Язык: Английский

---

The role of lipid components in lipid nanoparticles for vaccines and gene therapy

Advanced Drug Delivery Reviews, Год журнала: 2022, Номер 188, С. 114416 - 114416

Опубликована: Июль 3, 2022

Язык: Английский

---

The clinical progress of mRNA vaccines and immunotherapies

Nature Biotechnology, Год журнала: 2022, Номер 40(6), С. 840 - 854

Опубликована: Май 9, 2022

Язык: Английский

---

The landscape of mRNA nanomedicine

Nature Medicine, Год журнала: 2022, Номер 28(11), С. 2273 - 2287

Опубликована: Ноя. 1, 2022

Язык: Английский

---

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs

Nature Reviews Materials, Год журнала: 2023, Номер 8(4), С. 282 - 300

Опубликована: Янв. 19, 2023

Язык: Английский

---

Unlocking the promise of mRNA therapeutics

Nature Biotechnology, Год журнала: 2022, Номер 40(11), С. 1586 - 1600

Опубликована: Ноя. 1, 2022

Язык: Английский

---

CAR T therapy beyond cancer: the evolution of a living drug

Nature, Год журнала: 2023, Номер 619(7971), С. 707 - 715

Опубликована: Июль 26, 2023

Язык: Английский

---

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

Nature Medicine, Год журнала: 2021, Номер 27(12), С. 2085 - 2098

Опубликована: Дек. 1, 2021

Язык: Английский

---

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy

Advanced Materials, Год журнала: 2023, Номер 35(51)

Опубликована: Май 17, 2023

Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to success coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty Spikevax). To meet therapeutic purpose, it is required that must enter target cells express sufficient proteins. Therefore, development effective delivery systems necessary crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle indeed accelerated applications humans, as several mRNA‐based therapies have already been approved or are clinical trials. In this review, focus on mRNA‐LNP‐mediated anticancer therapy. It summarizes main strategies mRNA‐LNP formulations, discusses representative approaches cancer, points out current challenges possible future directions research field. hoped these delivered messages can help further improve application technology cancer

Язык: Английский

---

In vivo hematopoietic stem cell modification by mRNA delivery

Science, Год журнала: 2023, Номер 381(6656), С. 436 - 443

Опубликована: Июль 27, 2023

Hematopoietic stem cells (HSCs) are the source of all blood over an individual's lifetime. Diseased HSCs can be replaced with gene-engineered or healthy through HSC transplantation (HSCT). However, current protocols carry major side effects and have limited access. We developed CD117/LNP-messenger RNA (mRNA), a lipid nanoparticle (LNP) that encapsulates mRNA is targeted to cell factor receptor (CD117) on HSCs. Delivery anti-human CD117/LNP-based editing system yielded near-complete correction hematopoietic sickle cells. Furthermore, in vivo delivery pro-apoptotic PUMA (p53 up-regulated modulator apoptosis) CD117/LNP affected function permitted nongenotoxic conditioning for HSCT. The ability target offers regimen HSCT, this platform could basis genome cure genetic disorders, which would abrogate need

Язык: Английский

---